244 related articles for article (PubMed ID: 28318768)
1. Clinical development strategy for a candidate group A streptococcal vaccine.
Schödel F; Moreland NJ; Wittes JT; Mulholland K; Frazer I; Steer AC; Fraser JD; Carapetis J
Vaccine; 2017 Apr; 35(16):2007-2014. PubMed ID: 28318768
[TBL] [Abstract][Full Text] [Related]
2. An Experimental Group A
Rivera-Hernandez T; Carnathan DG; Jones S; Cork AJ; Davies MR; Moyle PM; Toth I; Batzloff MR; McCarthy J; Nizet V; Goldblatt D; Silvestri G; Walker MJ
mBio; 2019 Apr; 10(2):. PubMed ID: 31040243
[TBL] [Abstract][Full Text] [Related]
3. Development of Group A streptococcal vaccines: an unmet global health need.
Sheel M; Moreland NJ; Fraser JD; Carapetis J
Expert Rev Vaccines; 2016; 15(2):227-38. PubMed ID: 26559880
[TBL] [Abstract][Full Text] [Related]
4. Immune response against M protein-conserved region peptides from prevalent group A Streptococcus in a North Indian population.
Gupta VK; Sekhar S; Dhanda V; Toor D; Kumar R; Chakraborti A
J Microbiol Immunol Infect; 2016 Jun; 49(3):352-8. PubMed ID: 25087198
[TBL] [Abstract][Full Text] [Related]
5. Correlates of Protection for M Protein-Based Vaccines against Group A Streptococcus.
Tsoi SK; Smeesters PR; Frost HR; Licciardi P; Steer AC
J Immunol Res; 2015; 2015():167089. PubMed ID: 26101780
[TBL] [Abstract][Full Text] [Related]
6. Strategic development of the conserved region of the M protein and other candidates as vaccines to prevent infection with group A streptococci.
Good MF; Pandey M; Batzloff MR; Tyrrell GJ
Expert Rev Vaccines; 2015; 14(11):1459-70. PubMed ID: 26485214
[TBL] [Abstract][Full Text] [Related]
7. Molecular biology of Group A
Brahmadathan NK
Indian J Med Microbiol; 2017; 35(2):176-183. PubMed ID: 28681803
[TBL] [Abstract][Full Text] [Related]
8. Application of Transthoracic Echocardiography for Cardiac Safety Evaluation in the Clinical Development Process of Vaccines Against Streptococcus pyogenes.
Nakakana U; Serry-Bangura A; Edem BE; Tessitore P; Di Cesare L; Moriel DG; Podda A; De Ryck IS; Arora AK
Drugs R D; 2024 Mar; 24(1):1-12. PubMed ID: 38494581
[TBL] [Abstract][Full Text] [Related]
9. Vaccine development for group A streptococcus infections and associated disease.
Batzloff MR; Sriprakash KS; Good MF
Curr Drug Targets; 2004 Jan; 5(1):57-69. PubMed ID: 14738218
[TBL] [Abstract][Full Text] [Related]
10. A vaccine against Streptococcus pyogenes: the potential to prevent rheumatic fever and rheumatic heart disease.
Guilherme L; Ferreira FM; Köhler KF; Postol E; Kalil J
Am J Cardiovasc Drugs; 2013 Feb; 13(1):1-4. PubMed ID: 23355360
[TBL] [Abstract][Full Text] [Related]
11. A half-century of streptococcal research: then & now.
Krause RM
Indian J Med Res; 2002 Jun; 115():215-41. PubMed ID: 12440194
[TBL] [Abstract][Full Text] [Related]
12. Prospects for a group A streptococcal vaccine.
McMillan DJ; Chhatwal GS
Curr Opin Mol Ther; 2005 Feb; 7(1):11-6. PubMed ID: 15732524
[TBL] [Abstract][Full Text] [Related]
13. Group A streptococcal infections in children.
Steer AC; Danchin MH; Carapetis JR
J Paediatr Child Health; 2007 Apr; 43(4):203-13. PubMed ID: 17444820
[TBL] [Abstract][Full Text] [Related]
14. WHO/IVI global stakeholder consultation on group A Streptococcus vaccine development: Report from a meeting held on 12-13 December 2016.
Osowicki J; Vekemans J; Kaslow DC; Friede MH; Kim JH; Steer AC
Vaccine; 2018 Jun; 36(24):3397-3405. PubMed ID: 29496349
[TBL] [Abstract][Full Text] [Related]
15. Preferences for health outcomes associated with Group A Streptococcal disease and vaccination.
Lee GM; Salomon JA; Gay C; Hammitt JK
Health Qual Life Outcomes; 2010 Mar; 8():28. PubMed ID: 20226042
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the Potency, Neutralizing Antibody Response, and Stability of a Recombinant Fusion Protein Vaccine for Streptococcus pyogenes.
Burlet E; HogenEsch H; Dunham A; Morefield G
AAPS J; 2017 May; 19(3):875-881. PubMed ID: 28283948
[TBL] [Abstract][Full Text] [Related]
17. Immunization with a streptococcal multiple-epitope recombinant protein protects mice against invasive group A streptococcal infection.
Kuo CF; Tsao N; Hsieh IC; Lin YS; Wu JJ; Hung YT
PLoS One; 2017; 12(3):e0174464. PubMed ID: 28355251
[TBL] [Abstract][Full Text] [Related]
18. Vaccine Approaches To Protect against Group A Streptococcal Pharyngitis.
Fischetti VA
Microbiol Spectr; 2019 May; 7(3):. PubMed ID: 31111819
[TBL] [Abstract][Full Text] [Related]
19. Missing Piece Study protocol: prospective surveillance to determine the epidemiology of group A streptococcal pharyngitis and impetigo in remote Western Australia.
Barth DD; Mullane MJ; Sampson C; Chou C; Pickering J; Nicol MP; Davies MR; Carapetis J; Bowen AC
BMJ Open; 2022 Apr; 12(4):e057296. PubMed ID: 35387825
[TBL] [Abstract][Full Text] [Related]
20. Protein adhesins as vaccine antigens for Group A Streptococcus.
Raynes JM; Young PG; Proft T; Williamson DA; Baker EN; Moreland NJ
Pathog Dis; 2018 Mar; 76(2):. PubMed ID: 29718270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
